Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003101 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00003101: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00003101 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003101, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with autologous bone marrow transplantation or peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus bone marrow transplantation or peripheral stem cell transplantation in treating patients who have oligodendroglioma.
Interventions
- BIOLOGICAL filgrastim
- DRUG thiotepa
- DRUG busulfan
- DRUG lomustine
- DRUG procarbazine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 1997-08 |
| Est. Completion | 2002-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003101
The ClinicalTrials.gov registry entry for NCT00003101 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which filgrastim is the first listed.
NCT00003101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003101 about?
NCT00003101 is a clinical study titled "Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with autologous bone marrow transplantation or peripheral stem cell transplantation may allow doctors to give higher doses o...
What is the current status of trial NCT00003101?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 1997-08. Estimated completion is 2002-01.
What interventions are being tested in trial NCT00003101?
The interventions under investigation include: filgrastim (BIOLOGICAL), thiotepa (DRUG), busulfan (DRUG), lomustine (DRUG), procarbazine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003101?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.